Sevelamer's Effect on Blood Calcium and Phosphate Levels

Mechanism and Effect on Phosphate

• Sevelamer achieves control of serum phosphorus levels similar to calcium-based phosphate binders, meeting K/DOQI recommended targets, as demonstrated in randomized controlled trials 1, 2

Effect on Calcium Levels

• Sevelamer does not raise serum calcium because it contains no calcium, and it generally reduces serum calcium levels to a greater extent than calcium-based binders, resulting in significantly fewer hypercalcemic episodes 1, 2
• The K/DOQI guidelines strongly recommend adding sevelamer when patients require more than 2,000 mg/day of elemental calcium from calcium-based binders to decrease total calcium intake 1, 2

Clinical Advantages Over Calcium-Based Binders

• Sevelamer prevents progression of aortic and coronary artery calcification in patients with baseline vascular calcification, while calcium-based binders show significant progression 1, 2, 3
• Sevelamer reduces LDL cholesterol by 15-31% and total cholesterol significantly compared to calcium-based binders, providing additional cardiovascular benefit 1, 2, 4

Specific Clinical Scenarios for Sevelamer Use

• Use sevelamer in patients with hypercalcemia, elevated calcium-phosphorus product, or severe vascular calcification where calcium-based binders are contraindicated, as recommended by the National Kidney Foundation 3
• The National Kidney Foundation suggests considering sevelamer in patients with low-turnover bone disease who cannot incorporate calcium loads, predisposing them to extraskeletal calcification 3

Sevelamer Guidelines for Controlling Serum Phosphorus in CKD Patients

Introduction to Sevelamer Therapy

• The National Kidney Foundation recommends starting phosphate binders when serum phosphorus exceeds 4.6 mg/dL despite dietary restriction to 800-1,000 mg/day, or when intact PTH is elevated above target range in CKD stages 3-4 patients 5
• The American Journal of Kidney Diseases suggests that either calcium-based binders or sevelamer may be used as initial therapy in CKD stages 3-4 patients 5

Initiation and Dosing of Sevelamer

• The National Kidney Foundation recommends initiating phosphate binders when serum phosphorus exceeds 5.5 mg/dL despite dietary restriction in CKD stage 5 patients 5, 6
• The American Journal of Kidney Diseases states that both calcium-based binders and sevelamer are equally acceptable as first-line therapy in dialysis patients 5, 6
• The target serum phosphorus level for CKD stages 3-4 patients is 2.7-4.6 mg/dL, and for CKD stage 5 patients is 3.5-5.5 mg/dL 5

Specific Clinical Scenarios

• Sevelamer is preferred over calcium-based binders in patients with hypercalcemia, low PTH, excessive calcium load, or severe vascular calcification 5, 6, 7

Combination Therapy and Cost Considerations

• The National Kidney Foundation recommends combining calcium-based binders and sevelamer when hyperphosphatemia persists despite monotherapy 5, 6
• The American Journal of Kidney Diseases notes that sevelamer has higher acquisition costs than calcium-based binders, but may be justified by prevention of vascular calcification and reduced mortality 8

Sevelamer Administration in CKD Patients

Introduction to Sevelamer

• The American Journal of Kidney Diseases recommends administering sevelamer 10-15 minutes before or during meals to maximize phosphate binding efficacy, as the medication must be taken with food because phosphate binders work by binding dietary phosphorus in the gastrointestinal tract 9
• Sevelamer is the preferred phosphate binder over calcium-based alternatives in patients with hypercalcemia, elevated calcium-phosphorus product (>55 mg²/dL²), severe vascular calcification, or low PTH/adynamic bone disease, according to the American Journal of Kidney Diseases 9

Specific Clinical Scenarios for Sevelamer Use

• In patients with low-turnover bone disease, the American Journal of Kidney Diseases suggests that calcium-based binders should be avoided because the bone cannot incorporate calcium loads, predisposing to extraskeletal calcification 9

Sevelamer Dosage and Administration for Dialysis Patients

Dose Selection and Target Serum Phosphorus

• The National Kidney Foundation recommends targeting a serum phosphorus level of 3.5-5.5 mg/dL for dialysis patients, with dose adjustments made accordingly 10

Monitoring and Titration

• The American Journal of Kidney Diseases suggests monitoring serum phosphorus monthly following initiation of sevelamer therapy, with adjustments made to achieve the target serum phosphorus level of 3.5-5.5 mg/dL 10
• For patients with low PTH levels (<150 pg/mL), calcium-based binders should be avoided, making sevelamer the appropriate first-line agent, according to the American Journal of Kidney Diseases 10